Literature DB >> 27934140

A54 Peptide Modified and Redox-Responsive Glucolipid Conjugate Micelles for Intracellular Delivery of Doxorubicin in Hepatocarcinoma Therapy.

Na Liu1, Yanan Tan1, Yingwen Hu1, Tingting Meng1, Lijuan Wen1, Jingwen Liu1, Bolin Cheng1, Hong Yuan1, Xuan Huang2, Fuqiang Hu1.   

Abstract

Redox-responsive nanomaterials applied in drug delivery systems (DDS) have attracted an increasing attention in pharmaceutical research as a carrier for antitumor therapy. However, there would be unwanted drug release from a redox-responsive DDS with no selection at nontarget sites, leading to undesirable toxicities in normal tissues and cells. Here, an A54 peptide modified and PEGylated reduction cleavable glucolipid conjugate (A54-PEG-CSO-ss-SA, abbreviated to APCssA) was designed for intracellular delivery of doxorubicin (DOX). The synthesized APCssA could be assembled via micellization self-assembly in aqueous water above the critical micelle concentration (54.9 μg/mL) and exhibited a high drug encapsulation efficiency (77.92%). The APCssA micelles showed an enhanced redox sensitivity in that the disulfide bond could be degraded quickly and the drug would be released from micelles in 10 mM levels of glutathione (GSH). The cellular uptake studies highlighted the affinity of APCssA micelles toward the hepatoma cells (BEL-7402) compared to that toward HepG2 cells. In contrast with the nonresponsive conjugate, the drug was released from APCssA micelles more quickly in 10 mM level of GSH concentration (tumor cells). Moreover, the DOX-loaded APCssA micelles displayed an increased cytotoxicity which was 1.6- to 2.0-fold that of unmodified and nonresponsive micelles. In vivo, the APCssA micelles had stronger distribution to liver and hepatoma tissue and prolonged the circulation and retention time, while the drug release only occurred in the tumor tissue. The APCssA/DOX showed the tumor inhibition rate equal to that of commercial doxorubicin hydrochloric without negative consequence. This study suggested that the APCssA/DOX showed promising potential to treat the tumor for its special tumor targeting, selective intracellular drug release, enhanced antitumor activity, and reduced toxicity on normal tissues.

Entities:  

Keywords:  active targeting; chemotherapeutics cytotoxicity reduction; glycolipid-like micelles; redox-responsive; triggered release

Mesh:

Substances:

Year:  2016        PMID: 27934140     DOI: 10.1021/acsami.6b09333

Source DB:  PubMed          Journal:  ACS Appl Mater Interfaces        ISSN: 1944-8244            Impact factor:   9.229


  6 in total

Review 1.  Chemotherapy for hepatocellular carcinoma: The present and the future.

Authors:  Marco Le Grazie; Maria Rosa Biagini; Mirko Tarocchi; Simone Polvani; Andrea Galli
Journal:  World J Hepatol       Date:  2017-07-28

2.  Mitochondria-Responsive Drug Release along with Heat Shock Mediated by Multifunctional Glycolipid Micelles for Precise Cancer Chemo-Phototherapy.

Authors:  Yanan Tan; Yun Zhu; Lijuan Wen; Xiqin Yang; Xuan Liu; Tingting Meng; Suhuan Dai; Yuan Ping; Hong Yuan; Fuqiang Hu
Journal:  Theranostics       Date:  2019-01-24       Impact factor: 11.556

3.  Enhancing Drug Delivery for Overcoming Angiogenesis and Improving the Phototherapy Efficacy of Glioblastoma by ICG-Loaded Glycolipid-Like Micelles.

Authors:  Yupeng Liu; Suhuan Dai; Lijuan Wen; Yun Zhu; Yanan Tan; Guoxi Qiu; Tingting Meng; Fangying Yu; Hong Yuan; Fuqiang Hu
Journal:  Int J Nanomedicine       Date:  2020-04-22

4.  VEGF-mediated tight junctions pathological fenestration enhances doxorubicin-loaded glycolipid-like nanoparticles traversing BBB for glioblastoma-targeting therapy.

Authors:  Lijuan Wen; Yanan Tan; Suhuan Dai; Yun Zhu; Tingting Meng; Xiqin Yang; Yupeng Liu; Xuan Liu; Hong Yuan; Fuqiang Hu
Journal:  Drug Deliv       Date:  2017-11       Impact factor: 6.419

Review 5.  Peptide-based delivery of therapeutics in cancer treatment.

Authors:  Timothy Samec; Jessica Boulos; Serena Gilmore; Anthony Hazelton; Angela Alexander-Bryant
Journal:  Mater Today Bio       Date:  2022-03-30

6.  Reversing activity of cancer associated fibroblast for staged glycolipid micelles against internal breast tumor cells.

Authors:  Yun Zhu; Fangying Yu; Yanan Tan; Yun Hong; Tingting Meng; Yupeng Liu; Suhuan Dai; Guoxi Qiu; Hong Yuan; Fuqiang Hu
Journal:  Theranostics       Date:  2019-09-19       Impact factor: 11.556

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.